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MetastasisAbstract Aim of work: To detect the diagnostic value of PET/CT in breast cancer patients. We
compared the performance of PET/CT with that of conventional imaging in detection of recurrence
and distant metastasis and evaluated the impact PET/CT results have on disease free survival.
Materials and methods: We retrospectively studied 50 patients with breast cancer with clinical
suspicion of recurrent or metastatic lesion and who underwent PET/CT and conventional imaging
procedures. The imaging results were retrospectively compared with histopathology and clinical
follow-up as a reference standard.
Results: PET/CT detected distant metastases with a sensitivity of 97% and a speciﬁcity of 93%. In
contrast, the sensitivity and speciﬁcity of combined conventional imaging procedures were 75% and
73%, respectively, disease-free survival was signiﬁcantly shorter in the 34 M1-PET/CT patients than
in the 14 M0-PET/CT patients (log-rank P = 0.002) also PET/CT detected recurrence in 1 patient
with equivocal mammographic ﬁndings.
Conclusion: In breast cancer, PET/CT is superior to conventional imaging procedures for detection
of recurrence, distant metastases and PET/CT can be used to improve prediction of the clinical out-
come of breast cancer patients.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.1. Introduction
Breast cancer is the most frequent malignancy in women. Fol-
low-up for the early detection of recurrence is important
because the 5-y survival of patients with disseminated disease
is signiﬁcantly shorter than that of those who have only regio-
nal disease. The availability of various new therapies for
relapsing breast cancer makes early detection as well as deter-
mination of the extent of disease and its precise localization of
utmost importance (1).
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cer have contributed to a signiﬁcant decrease in breast cancer-
related mortality over the past 20–30 years. Breast conserving
surgery (BCS) with radiation results in survival outcomes sim-
ilar to those of mastectomy with local recurrence in the ipsilat-
eral breast of 6–9% at 5 years and 14–20% at 20 years. Early
detection of asymptomatic local recurrence via appropriate
surveillance techniques, including breast imaging, improves
long-term survival when compared to late symptomatic detec-
tion. Therefore sensitive, non-invasive, and cost-effective sur-
veillance strategies to detect early local recurrence are
necessary (2).
In breast cancer, the role of PET is not clearly deﬁned. Sev-
eral efﬁcient imaging tools including mammography, magnetic
resonance imaging (MRI), bone scans (BS) and CT scans are
widely available, making the implementation of yet another
modality a challenging process. Published data suggest that
PET is not reliable in evaluating the primary tumor or accu-
rately staging the axillary disease. In primary staging, PET
has been shown to be inferior to conventional imaging because
of its low accuracy and its association with noticeable numbers
of false-negative results (3).
However, recent literature suggests that PET/CT is appro-
priate for restaging of breast cancer patients with documented
or suspected recurrent breast cancer. It accurately detects
abnormal extra-axillary lymph nodes, detects distant metasta-
ses, and often demonstrates recurrent and/or distant disease
prior to conventional imaging modalities (4). Evaluation of
breast cancer patients with 18FDG PET or 18FDG PET–CT
allows for survey of the chest, abdomen and bones in a single
examination with both anatomic and metabolic information
useful in the staging, restaging and assessing for therapeutic
response. In the setting of asymptomatic patients with rising
tumor markers the use of PET/CT may result in early detec-
tion of disease and a signiﬁcant change in management (5).
In a recent prospective study involving locally advanced or
inﬂammatory breast cancer patients, 18FDG PET–CT outper-
formed conventional imaging for the detection of bone and
liver metastasis as well as distant lymph node involvement
leading to a change in clinical stage in 61 of 117 patients
(52%) (4).
NCCN guidelines suggest the following for staging evalua-
tion of women with recurrent or metastatic breast cancer: diag-
nostic chest CT, bone scan, and radiographs of painful long
bones or those with abnormal appearance. CT of the abdomen
with or without the pelvis may also be considered for restag-
ing. PET/CT is considered an optional modality in this setting
and should be considered in situations where standard imaging
results are equivocal or suspicious (6).
In this retrospective study, we aimed to detect the diagnos-
tic value of PET/CT in breast cancer patients. We compared
the performance of PET/CT with that of conventional imaging
in detection of recurrence and distant metastasis and examined
the impact PET/CT results on survival.
2. Materials and methods
2.1. Patients
This retrospective study includes 50 eligible female patients
with a history of breast cancer. This study was done fromAugust 2011to December 2013. The diagnosis was based on
clinical examination, bilateral mammography and ultrasonog-
raphy of the breast and axilla and it was biopsy-conﬁrmed in
all patients. All patients underwent conventional imaging stud-
ies and PET/CT to search for recurrence or distant metastases.
Exclusion criteria were patients whose information was
incomplete or where PET/CT images were unavailable, other
exclusion were diabetes mellitus, pregnancy, and patients
younger than 18 year.
All patients gave written informed consent to review their
medical studies according to ethics committee guidelines.
2.2. Treatment
Treatment consisted of neoadjuvant chemotherapy, followed
by surgery, loco-regional radiotherapy, and hormonal therapy
according to the subtype of breast cancer.
2.3. Follow up
For follow up: regular history, physical examination, and
mammography were recommended, physical examinations
should be performed every 3–6 months for the ﬁrst 3 years,
every 6–12 months for years 4 and 5, and annually thereafter.
For women who have undergone breast-conserving surgery
(mastectomy), a post-treatment mammogram should be
obtained 1 year after the initial mammogram and at least
6 months after completion of radiation therapy. If indicated,
a yearly mammographic evaluation should be performed.
The use of complete blood counts, chemistry panels, bone
scans, chest radiographs, liver ultrasounds, pelvic ultrasounds,
computed tomography scans, [18F] ﬂuorodeoxyglucose–posi-
tron emission tomography scans, magnetic resonance imaging,
and/or tumor markers (carcinoembryonic antigen, CA 15-3,
and CA 27.29) is not recommended for routine follow-up in
an otherwise asymptomatic patient with no speciﬁc ﬁndings
on clinical examination (7). The follow up period ranged
between 6 months and 36 months with a median of 14 months.
2.4. Methods
2.4.1. Conventional imaging
Conventional studies to detect recurrence or distant metastasis
were performed according to routine practice in our institution
and consisted of bone scanning, chest examination by X-ray
and contrast enhanced CT scan and abdomino-pelvic exami-
nation by ultrasonography or contrast-enhanced CT.
In this study, 14 patients had bone scan, 14 patients had
chest radiography; 7 patients had CT of the chest; 2 of them
had high resolution CT scan, 13 patients had abdominal ultra-
sound, and 12 patients had CT of the abdomen and pelvis.
Conventional imaging was performed within 1 month preced-
ing the PET/CT scan (mean, 14 days; range, 5–33 days).
2.4.2. PET/CT
All patients were imaged with a dedicated PET–CT scanner (Sie-
mens, Biograph-2). All patients were fasted for at least 6 h before
FDG injection. Fasting blood glucose level of less than 150 mg/
dl was a requirement in all patients. The scan started 60 min
after intravenous administration of 2.516 MBq (0.068 mCi/kg)
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out talking. CT was performed from the skull base to pelvis by
performing a scout view followed by a spiral CT with 80 mA,
140 kVp. No oral contrast was given, and water only was used
to delineate bowel. Intravenous 130 ml of iohexol (Omnipaque
300 mg iodine/ml) was administered. On completion of CT,
2D PET emission data (4 min per bed position covering an axial
FOV of 15.7 cm with a 3-slice overlap) were obtained. The total
scanning time varied between 25 and 30 min for every patient.
The CT, PET and PET/CT images were reconstructed in
trans-axial, coronal and sagittal planes.
2.5. Image interpretation
A PET/CT scan is deﬁned as positive for metastasis if there is
abnormal FDG uptake greater than background in surround-
ing tissue and unrelated to physiologic sites of tracer uptake
(e.g. bowel, myocardium), without a speciﬁc standardized
uptake value (SUV) cut-off and a PET/CT scan is deﬁned as
negative if no 18F-FDG uptake. For residual hepatic or sple-
nic lesion, abnormal uptake was deﬁned as FDG accumulation
greater than in the liver (8).2.6. Reference standard
The ﬁnal diagnosis of recurrence or distant metastasis was
made after histo-pathological analysis, clinical and imaging
follow-up. In each case, we determined the indication for the
scan, the result, concordance/discordance with other conven-
tional imaging modalities and if the use of PET/CT had altered
patient management.2.7. Statistical analysis
Sensitivity, speciﬁcity, positive predictive value and negative
predictive value were determined on the basis of number of
patients, not number of lesions. Disease-free survival (DFS)
(or recurrence-free survival) is deﬁned as the time from ran-
domization to the ﬁrst of recurrence or relapse, second cancer,
or death. DFS was measured in patients with and without dis-
tant metastases discovered on PET/CT, and comparisons
between the 2 groups were assessed with using the Kaplan–
Meier method and Log-rank test (log-rank P= 0.002). The
analyses were performed using SAS version 9.1 (SAS Inc.,
Cary, NC).3. Results
3.1. Patients and tumor characteristics
A total number of 50 female patients with a history of breast
cancer were included in this study. The main indication for car-
rying out PET/CT scans was high clinical suspicion (signs or
symptoms) of recurrence or distant metastasis. The age of
patients ranged from 25 to 80 years with mean age being
50.85 years. Patient and tumor characteristics before PET/
CT and conventional images are listed in Table 1. As regards
the histo-pathological character of the tumor, 30 out of 50
patients (60%) had invasive ductal carcinoma.Regarding treatment: surgery (modiﬁed radical mastec-
tomy, lumpectomy and axillary lymph node resection for all
patients), chemotherapy, and radiotherapy in 24 patients; sur-
gery was followed by chemotherapy in 6 patients; surgery and
radiotherapy were performed on 5 patients; surgery only was
performed on 4 patients, and chemotherapy was performed
on only 1 patient. Hormonal treatment with other lines of
treatment had been administered to 10 patients.
Thirty-four (68%) out of 50 patients show positive estrogen
receptor status while 32 patients (64%) show positive proges-
terone status.
Regarding tumor markers, 44 out of 50 patients (88%)
showed an increased level of CA 15-3.
3.2. Value of PET/CT scan
Distant metastases were visualized on PET/CT in 35 patients
(70%). Sites of distant involvement in the 35 patients included
bone (n= 15), distant lymph nodes (n= 6), liver (n= 7), and
lung (n= 6) Table 2. Additional chemotherapy was done for
metastatic disease, some liver metastases were operated or
treated by radiofrequency, and some bone lesions were treated
by radiation therapy in the site of the lesion. In this study,
PET/CT detected recurrence in 1 patient, this patient was
referred for PET/CT scan because of elevated tumor markers
and her mammography was equivocal (area of increased den-
sity). The patient showed increased FDG uptake in residual
left breast tissue 2 years after left lumpectomy, a biopsy was
performed and showed evidence of recurrence and the patient
underwent mastectomy.
3.3. Comparison between PET/CT and conventional Imaging to
detect distant metastasis in 35 patients with breast cancer
We compare the performance of both PET/CT and conven-
tional imaging techniques to detect distant metastasis in 35
patients with breast cancer (Table 3).
For bone lesions, PET/CT detected bone metastases in 15
out of 35 patients. Bone scanning revealed metastases in 8 of
these patients. Bone scanning could not detect lesion in 3
patients which was considered as false negative results, and
showed false positive results in 4 patients with benign osteoar-
ticular lesions.
The performance of PET/CT and conventional imaging in
detecting distant extra-axillary lymph node metastases was
evaluated separately at the supradiaphragmatic and infradia-
phragmatic levels. Of 35 female patients; 4 showed supradia-
phragmatic (cervical, mediastinal, or contralateral axillary)
lymph node involvement on PET/CT. Contrast-enhanced CT
missed mediastinal lymph nodes in 1 patient. Chest radiogra-
phy did not detect involved lymph nodes in any patient. Two
patients had PET/CT evidence of abdominal and pelvic lymph
node involvement. Pelvic lesion in 1 patient disappeared with
no therapy on a repeat CT study performed 3 months later
and tumor markers returned to normal values and these ﬁnd-
ings represented an inﬂammatory process (false positive
result). Among these 2 patients, conventional imaging was
false-negative in the ﬁrst (did not show the lesion) and false
positive in the second like PET/CT.
For the detection of liver metastases, the performance of
PET/CT was compared with that of abdominal CT and
Table 1 Patients and tumor characteristics.





Invasive ductal carcinoma 30 60%
Inﬂammatory carcinoma 9 60%
Invasive lobular carcinoma 7 14%
Undiﬀerentiated carcinoma 4 8%
Treatment
Surgery, chemo- & radiotherapy 24 48%
Surgery & chemotherapy 6 12%
Surgery & radiotherapy 5 10%
Surgery only 4 8%
Chemotherapy only 1 2%









Values of tumor markers at time of suspected recurrence or distant
recurrence
CA 15-3 44 88%
CEA 1 2%
Both CA 15-3 and CEA 5 10%
CA 15-3: cancer antigen 15-3, CEA: Carcinoembryonic antigen.
a Hormonal therapy with other line of treatment had been
administered to 10 patients.
Table 2 The distribution of recurrence and distant metastasis
in 35 patients detected by PET/CT.
Site of recurrence Percentage of patients (n)
Bone 15 (30%)
Extra-axillary lymph node area 6 (12%)
Liver 7 (14%)
Lung 6 (12%)
Local recurrence 1 (2%)
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showed liver metastases. PET/CT detected liver metastases in
all 6 patients and showed a metastasis in an additional patient
in whom ultrasonography was negative, and the case was con-
ﬁrmed by imaging follow-up. In 1 patient, PET/CT helped to
settle doubtful ﬁndings on conventional imaging. In this
patient, liver ultrasonography was suggestive of metastasis
(false-positive result) but PET/CT and MR imaging were
negative.
For lung evaluation, 6 out of the 35 patients had metastatic
large pulmonary nodules detected by CT as well as by PET/
CT. High resolution CT showed evidence of septal thickening
with a small subcentimetric metastatic nodule in 1 patient that
was missed by PET/CT.In total, in this series of 50 patients with breast cancer PET/
CT detected all distant lesions evidenced by the combination of
conventional imaging, except in 1 case (of small pulmonary
Nodule with septal thickening), also PET/CT showed addi-
tional unknown lesions in bone, distant lymph nodes, and
liver. Distant metastases were visualized on PET/CT in 35
patients. Only 25 of these 35 patients (71%) had distant metas-
tases in conventional imaging.
PET/CT was positive in 35 cases and negative in 15 cases of
all 50 patients included in the study, there were 34 true-positive
and 14 true-negative cases, 1 patient showed false negative
result and 1 patient showed false positive result so PET/CT
has a sensitivity of 97% and a speciﬁcity of 93%, positive pre-
dictive value 97% and negative predictive value 93% Table 4.
Conventional imaging procedures were positive in 25 cases
and negative in 25 cases of all 50 patients included in the study,
there were 18 true-positive and 19 true-negative cases, 5
patients showed false negative result and 6 patients showed
false positive result so conventional imaging procedures had
a sensitivity of 75%, and a speciﬁcity of 73%, positive predic-
tive value 72% and negative predictive value 76% (Table 4).
3.4. Relationship between PET/CT ﬁndings and survival
Among the 50 evaluable patients with adequate follow up,
PET/CT showed distant metastases in 34 patients while 15
patients showed no metastasis. Disease-free survival was sig-
niﬁcantly shorter in the 34 M1-PET/CT female patients than
in the 15 M0-PET/CT female patients (log-rank P= 0.002),
the median survival was 25 months for patients with metastasis
and more than 60 months for no metastatic patients (Fig. 1).
3.5. Cases
Figs. 2–4 demonstrate a sample of selected cases of our study,
each ﬁgure outlines one case.
4. Discussion
Worldwide, breast cancer is the most frequently diagnosed life-
threatening cancer in women and a leading cause of death (9).
Monitoring treatment responses for women with metastatic
breast cancer can be difﬁcult and with the goals of therapy
focused on improving quality of life and overall survival, ﬁnd-
ing a test that is safe, non-invasive and reliable to assess
response is a challenge (5). In this retrospective study which
includes 50 patients with breast cancer, we try to detect the
diagnostic value of PET/CT in breast cancer patients. We com-
pared the performance of PET/CT with that of conventional
imaging in detection of recurrence and distant metastasis. In
this study, PET/CT provided powerful information that had
an impact on management in 35 out of 50 patients with breast
cancer (70%) whereas PET/CT revealed distant metastases in
34 patients and evidence of recurrence in 1 patient.
The strengths of PET are well recognized. It is a whole-
body scan that allows the visualization of metabolic changes
that usually precede anatomical changes; it is more sensitive
than and equally speciﬁc to other imaging modalities in detect-
ing small lesions (5–10 mm), particularly lymph nodes as well
as visceral and bone disease. CT has a distinct advantage in
detecting small lung and liver metastases. In combination, they
Table 4 Diagnostic performance of conventional imaging and
PET/CT in 35 patients with breast cancer.
Conventional PET
True positive 18 34
True negative 19 14
False positive 6 1











(ultrasound or contrast enhanced CT)
Total
Bone 15 8 – – 15
Extra-axillary LN 6 2 2 6
Liver 7 6 7
Lung 6 7 7
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olution that could potentially replace conventional imaging in
at least some aspects of breast cancer management (3).
Our study strongly supports the conclusions of previous
studies that have shown that PET/CT is more accurate than
conventional imaging for the detection of distant metastases
(10,11).
In our study, PET/CT detected metastatic disease with a
sensitivity, speciﬁcity, positive predictive value and negative
predictive value of 97% and 93%, 97% and 93%, respectively.
The diagnostic performance of PET/CT in our study is in line
with the study of Aukema et al. (12) which included 56 patients
with suspected locoregional breast cancer recurrence and dis-Fig. 1 Kaplan-Meier plot of disease-free survival for 34 female
patients with positive PET/CT scan of metastasis versus 14
patients with negative PET/CT scan of metastasis.tant metastasis. The sensitivity, speciﬁcity, positive and nega-
tive predictive values of PET/CT were respectively 97%,
92%, 95% and 94%.
The Chinese investigators also reported a similar conclu-
sion that PET–CT is useful in the detection of recurrent and
metastatic disease in breast cancer (13).
In our study, PET/CT has higher sensitivity and speciﬁcity
than conventional imaging in the detection of distant metasta-
ses of breast cancer as conventional imaging procedures had a
sensitivity of 75%, and a speciﬁcity of 73%, positive predictive
value 72% and negative predictive value76% and this result
agrees with the result of Niikura et al. (14) who performed a
retrospective review which included 225 patients with primary
breast cancer and compared the sensitivity and speciﬁcity of
PET/CT and conventional imaging (CT, ultrasonography,
radiography, and skeletal scintigraphy) for the detection of
distant metastases and they concluded that, in the detection
of such metastases, PET/CT was superior to conventional
imaging in terms of both sensitivity and speciﬁcity.
In this study, we performed a detailed analysis for different
metastatic locations.
Bone is the most frequent site of distant involvement in
breast cancer (15). In our study, all osseous metastases
detected by bone scan were also detected by PET/CT. Seven
additional cases were detected only by PET/CT and our results
are in agreement with other recent studies (16,17).
However, in the present study, similar to the practice in
most PET/CT centers, data were acquired from the mid-thigh
level to the base of the skull, with the arms raised. Most of the
skull, upper extremities, and lower extremities would not be
included in the imaged ﬁeld of view. On the other hand,
whole-body bone scanning is a true whole-body method. So,
some investigators advised performing bone scanning in addi-
tion to 18F-FDG imaging (3).
Regarding pulmonary parenchyma, PET/CT efﬁciently
detected supra-centimetric pulmonary nodules. However,
because of the partial-volume effect and respiratory move-
ments, PET lacked sensitivity for smaller nodules, reporting
of the CT part of the PET/CT examination obviously
improved the sensitivity of PET/CT in comparison to stand-
alone PET. However, free-breathing CT remains less efﬁcient
than standard diagnostic thoracic CT (10). In our study
PET/CT missed a small metastatic nodule in 1 patient.
18F-FDG-avid mediastinal lymph node metastases are not
rare in cases of locally advanced breast carcinoma or inﬂam-
matory carcinoma (16).
PET/CT was important in our study in detecting metastasis
of extra-axillary nodal regions, such as supraclavicular, inter-
nal mammary, and mediastinal lesions. Bernsdorf et al. (18)
reported that PET/CT solely detected six cases of distant
metastasis and 12 cases of extra-axillary LN involvement, in
Fig. 2 A female patient aged 52 years who underwent lumpectomy for inﬁltrating ductal carcinoma in the lower inner quadrant of the
left breast. Despite several cycles of chemotherapy, the levels of tumor markers rose. Work-up for recurrent or residual disease included
mammography, bone scan, and CT of the chest, abdomen, and pelvis, but the results were negative for recurrence. (A) Cranio-Caudal
mammogram shows: mild increased density with no deﬁnite lesion could be seen. (B) Axial fused PET/CT image shows: focal area of
increased uptake (white left arrow) in left breast. (C) Axial non contrast CT scan of the same patient shows multiple enlarged right axillary
lymph nodes (white star) but coronal whole body fused PET/CT images (D) showed: no active uptake indicating nonspeciﬁc benign
looking axillary lymph nodes. The uptake was present only in the site of previous lumpectomy.
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cer above 2 cm and because they studied bone scan, abdomen
ultrasonography, chest X-ray, and blood samples on conven-
tional staging, they stated that PET/CT could be only diagnos-
tic modality of the metastasis work up (18). In our patients, 4
out of 35 patients (11%) had lymph node involvement in the
thorax. Lymph nodes larger than 1 cm were easily detected
by enhanced CT in our study, as they were in others (14,16)
however post-contrast CT scan missed the diagnosis in 1
patient with medistinal lymph node and another patient with
inguinal lymph node. The only false positive lesion with
PET/CT was in the inguinal region which was proved by fol-
low up to be due to an inﬂammatory process.
In agreement with the recent report of Koolen et al. (16),
chest radiography did not detect mediastinal lymph node
metastases in any patient.
The liver is the main site of visceral breast cancer metasta-
ses; however, only little information is available regarding the
detection of liver metastases with FDG–PET (15).
18F-FDG PET/CT had sensitivity for liver metastases sim-
ilar to that of conventional imaging, PET/CT helped to classifydoubtful ﬁndings on conventional imaging (angiomas and
cysts), as also reported by Garami et al. (19). In this study
PET/CT detected liver metastases in all 6 patients and showed
a metastasis in an additional patient in whom ultrasonography
was negative, and the case was conﬁrmed by imaging follow-
up. In 1 patient, PET/CT helped to settle doubtful ﬁndings
on conventional imaging because liver ultrasonography was
suggestive of metastasis (false-positive result) but PET/CT
and MR imaging were negative.
In our study, PET/CT detected recurrence in 1 patient, her
mammography was equivocal (area of increased density). The
patient showed increased FDG uptake in residual left breast
tissue 2 years after left lumpectomy, a biopsy was performed
and showed evidence of recurrence, our result agrees with
the result of Manohar et al. (20) who analyzed the data of
111 patients who underwent FDG PET/CT and were sus-
pected of having recurrent breast carcinoma and they con-
cluded that F-18 FDG PET/CT is a very sensitive and
speciﬁc imaging tool in detecting and restaging recurrent
breast carcinoma. It can be a very useful imaging tool for
restaging locoregional recurrences.
Fig. 3 A female patient aged 43 years in whom inﬁltrating carcinoma of the left breast was diagnosed. Despite the patient undergoing
left mastectomy and high-dose chemotherapy, the cancer progressed. 1 year after diagnosis, high resolution CT (HRCT) (A)–(C) scan
showed evidence of a small-pleural based-metastatic nodule (9 mm) (white arrow) associated with mild septal thickening but coronal
whole body fused PET/CT images (D) missed the nodule and the septal thickening.
Fig. 4 Lymphatic spread of breast cancer in a 40-year-old woman who underwent lumpectomy and axillary node dissection for
inﬁltrating lobular carcinoma in the left breast. She received adjuvant chemotherapy and radiation therapy to the breast and axillary
region. Two years after surgery, levels of tumor markers were elevated. (A) Post contrast CT scan of the pelvis shows small lymph nodes in
the right inguinal region (white arrow) only but coronal whole body fused PET/CT images (B) show extensive enlarged inguinal lymph
nodes on both sides, a ﬁnding suspicious for metastasis. The patient subsequently received inguinal radiation therapy in addition to
chemotherapy.
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not recommend the use of PET/CT in clinical stage I, II, or
operable III breast cancer as an option, suggesting its use when
ﬁndings on conventional imaging are equivocal (6). PET/CT is
a fairly recent technique, and the relationship between initial
staging with PET/CT and survival has not yet been extensively
studied (11).
Alberini et al. (21) followed a group of 42 patients with
inﬂammatory carcinoma (median follow-up, 44 mo) (14). They
found a trend toward longer survival for M0 than for M1
patients––a trend that nearly reached signiﬁcance (P= 0.06).
In another study which included 104 evaluable patients, they
found a signiﬁcantly longer disease-speciﬁc survival in the 64
M0-patients than in the 40 women with distant metastases evi-
denced by PET/CT 11. In our study Disease-free survival was
signiﬁcantly shorter in the 34 M1-PET/CT female patients
than in the 15 M0-PET/CT female patients (log-rank
P= 0.002), the median survival was 25 months for patients
with metastasis and more than 60 months for no metastatic
patients.
Our study has some limitations. First, it was a retrospective
study. Second, not all of the patients underwent all types of
conventional imaging. Third, histo-pathologic ﬁndings were
not available for all patients with suspected distant metastases
so we do not know whether or not the patient with false-neg-
ative PET/CT scan who did not undergo biopsy, actually had
distant metastases.
5. Conclusion
From our study we can conclude that: PET/CT was superior
to conventional imaging in the detection of distant metastases
in patients with breast cancer and when we compare the over-
all diagnostic performance of PET/CT to other diagnostic con-
ventional imaging procedures, we found that PET/CTEA: had
clinically relevant advantages in the detection of extra-axillary
lymph node metastases particularly if the nodes were not
enlarged. PET/CT also detected bone metastases with higher
accuracy compared with bone scan. On the other hand, CT
had distinct advantages in the identiﬁcation of both small lung
and liver metastases. Thus, combined PET/CT could replace
the other conventional imaging procedures and detect recur-
rence and distant metastases in breast cancer patients.
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